Piramal Pharma Limited has completed the acquisition of a majority stake in Yapan Bio Private Limited, enhancing its capabilities in biologics manufacturing and development.

Piramal Pharma Limited has successfully acquired a majority stake in Yapan Bio Private Limited, enhancing its capabilities in the biopharmaceutical sector.

Piramal Pharma Limited successfully acquires a controlling stake in Yapan Bio Private Limited, enhancing its capabilities in biologics and vaccines.

Digital Marketing Agency Auckland NZ Adcelerate is a wor...

Piramal Pharma Solutions has initiated a $90 million expansion plan at two US facilities to boost production capabilities, enhancing its ADC offerings.

Piramal Pharma Solutions has launched a $90 million expansion for its U.S. facilities, enhancing production capacity and capabilities in critical drug technologies.

Piramal Pharma Solutions has announced a significant $90 million investment to enhance its two U.S. facilities. This expansion will boost manufacturing capabilities for critical drug development.

Piramal Pharma Ltd. invests $90 million in expanding two U.S. sites, enhancing capabilities for sterile injectables and drug development, underpinning commitment to innovation.

Piramal Pharma Limited announces a $90 million investment for expanding two vital U.S. facilities. This strategic move aims to enhance its manufacturing capabilities and meet growing demand.

Piramal Pharma Solutions is investing $90M to expand two of its U.S. facilities, adding commercial-scale manufacturing capabilities and significantly enhancing the capacity and efficiency of each site. Both facilities undergoing expansions are essential components of Piramal Pharma’s integrated antibody-drug conjugate (ADC) offering, ADCelerate™, reflecting the company’s commitment to delivering innovative solutions that align with patient …